Management: Prenatal Care, Preparation (Where? When?)

Dr. Hazal Kutlucan1
Prof. Dr. Aykan Yücel2

1Department of Obstetrics and Gynecology, TOBB Economy and Technology University Faculty of Medicine, Ankara, Türkiye
2University of Health Sciences, Ankara Bilkent City Hospital, Department of Perinatology, Ankara, Türkiye

ABSTRACT

The incidence of placenta accreta spectrum (PAS) is significantly rising as a consequence of highly increasing cesarean deliveries globally. An accurate prenatal diagnosis is crucial first step in management and prepara- tion for delivery. PAS is potentially life-threatening condition. Regular and frequent antenatal monitoring is essential in cases of PAS. Correction of anemia and optimizing hemoglobin levels before delivery are crucial. Admitting patients 5 to 7 days prior to procedure helps them to receive all necessary care and interventions. Multidisciplinary approaches with experienced healthcare workers and units including perinatologist, experi- enced pelvic surgeon, neonatologist, urologist, pulmonologist, interventional radiologist, intensive care unit and blood bank for emergent bleedings and creating centers of excellence for PAS will decrease the morbidity and mortality rates.

Keywords: Placenta accreta spectrum; Correction of anemia; Centers of excellence; Prenatal care; Multidisciplinary care team

Referanslar

  1. Shellhaas CS, Gilbert S, Landon MB, Varner MW, Leveno KJ, Hauth JC, et al. The frequency and complication rates of hysterectomy accompanying cesarean delivery. Obstet Gynecol. 2009;114(2 Pt 1):224-9. [Crossref]  [PubMed]
  2. Chawla J, Arora D, Paul M, Ajmani SN. Emergency Ob- stetric Hysterectomy: A Retrospective Study from a Teach- ing Hospital in North India over Eight Years. Oman Med J. 2015;30(3):181-6. [Crossref]  [PubMed]
  3. Iacovelli A, Liberati M, Khalil A, Timor-Trisch I, Leom- broni M, Buca D, et al. Risk factors for abnormally inva- sive placenta: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2020;33(3):471-81. [Crossref]  [PubMed]
  4. Silver RM, Branch DW. Placenta Accreta Spectrum. N Engl J Med. 2018;378(16):1529-36. [Crossref]  [PubMed]
  5. Lyell DJ, Faucett AM, Baer RJ, Blumenfeld YJ, Druzin ML, El-Sayed YY, et al. Maternal serum markers, characteristics and morbidly adherent placenta in women with previa. J Peri- natol. 2015;35(8):570-4. [Crossref]  [PubMed]
  6. Ersoy AO, Oztas E, Ozler S, Ersoy E, Erkenekli K, Uygur D, et al. Can venous ProBNP levels predict placenta accreta? J Matern Fetal Neonatal Med. 2016;29(24):4020-4. [Crossref]  [PubMed]
  7. Buca D, Liberati M, Cali G, Forlani F, Caisutti C, Flacco ME, et al. Influence of prenatal diagnosis of abnormally invasive placenta on maternal outcome: systematic review and me- ta-analysis. Ultrasound Obstet Gynecol. 2018;52(3):304-9. [Crossref]  [PubMed]
  8. Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, et al. Effect of predelivery diag- nosis in 99 consecutive cases of placenta accreta. Ob- stet Gynecol. 2010;115(1):65-9. [Crossref]  [PubMed]
  9. Bailit JL, Grobman WA, Rice MM, Reddy UM, Wapner RJ, Varner MW, et al. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125(3):683-9. [Crossref]  [PubMed]
  10. Berkley EM, Abuhamad AZ. Prenatal diagnosis of placen- ta accreta: is sonography all we need? J Ultrasound Med. 2013;32(8):1345-50. [Crossref]  [PubMed]
  11. Comstock CH, Bronsteen RA. The antenatal diagnosis of pla- centa accreta. BJOG. 2014;121(2):171-81; discussion 81-2. [Crossref]  [PubMed]
  12. Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean deliv- ery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(1):27-36. [Crossref]  [PubMed]
  13. Eller AG, Bennett MA, Sharshiner M, Masheter C, Soisson AP, Dodson M, et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol. 2011;117(2 Pt 1):331-7 https://doi.org/10.1097/AOG.0b013e3182051db2 https://www.ncbi.nlm.nih.gov/pubmed/21309195 [Crossref]
  14. Shamshirsaz AA, Fox KA, Salmanian B, Diaz-Arras- tia CR, Lee W, Baker BW, et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol. 2015;212(2):218 e1-9. [Crossref]  [PubMed]
  15. Comstock CH, Love JJ, Jr., Bronsteen RA, Lee W, Vettraino IM, Huang RR, et al. Sonographic detection of placen- ta accreta in the second and third trimesters of pregnancy. Am J Obstet Gynecol. 2004;190(4):1135-40. [Crossref]  [PubMed]
  16. Warshak CR, Eskander R, Hull AD, Scioscia AL, Mattrey RF, Benirschke K, et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta ac- creta. Obstet Gynecol. 2006;108(3 Pt 1):573-81. [Crossref]  [PubMed]
  17. Twickler DM, Lucas MJ, Balis AB, Santos-Ramos R, Mar- tin L, Malone S, et al. Color flow mapping for myometrial invasion in women with a prior cesarean delivery. J Matern Fetal Med. 2000;9(6):330-5. [Crossref]  [PubMed]
  18. Comstock CH. Antenatal diagnosis of placenta accreta: a re- view. Ultrasound Obstet Gynecol. 2005;26(1):89-96. [Crossref]  [PubMed]
  19. Palacios-Jaraquemada JM, Bruno CH. Utility of MRI in Placenta Accreta Spectrum for the Surgical Team. AJR Am J Roentgenol. 2021;217(5):1257. [Crossref]  [PubMed]
  20. Finazzo F, D'Antonio F, Masselli G, Forlani F, Palacios-Ja- raquemada J, Minneci G, et al. Interobserver agreement in MRI assessment of severity of placenta accreta spectrum disorders. Ultrasound Obstet Gynecol. 2020;55(4):467-73. [Crossref]  [PubMed]
  21. Palacios Jaraquemada JM, Bruno CH. Magnetic resonance imaging in 300 cases of placenta accreta: surgical correlation of new findings. Acta Obstet Gynecol Scand. 2005;84(8):716-24. [Crossref]  [PubMed]
  22. Dwyer BK, Belogolovkin V, Tran L, Rao A, Carroll I, Barth R, et al. Prenatal diagnosis of placenta accreta: sonography or magnetic resonance imaging? J Ultra- sound Med. 2008;27(9):1275-81. [Crossref]  [PubMed]
  23. D'Antonio F, Iacovella C, Bhide A. Prenatal identification of invasive placentation using ultrasound: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2013;42(5):509-17. [Crossref]  [PubMed]
  24. Silver RM. Abnormal Placentation: Placenta Previa, Vasa Pre- via, and Placenta Accreta. Obstet Gynecol. 2015;126(3):654-68. [Crossref]  [PubMed]
  25. Silver RM, Fox KA, Barton JR, Abuhamad AZ, Simhan H, Huls CK, et al. Center of excellence for placenta accre- ta. Am J Obstet Gynecol. 2015;212(5):561-8. [Crossref]  [PubMed]
  26. Pettit KE, Stephenson ML, Truong YN, Henry D, Murphy A, Kim L, et al. Maternal and neonatal outcomes among sched- uled versus unscheduled deliveries in women with prenatally diagnosed, pathologically proven placenta accreta. J Matern Fetal Neonatal Med. 2019;32(6):927-31. [Crossref]  [PubMed]
  27. Morlando M, Schwickert A, Stefanovic V, Gziri MM, Pateisky P, Chalubinski KM, et al. Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: A multinational database study. Acta Obstet Gynecol Scand. 2021;100 Suppl 1:41-9. [Crossref]  [PubMed]
  28. Bartels HC, Rogers AC, O'Brien D, McVey R, Walsh J, Bren- nan DJ. Association of Implementing a Multidisciplinary Team Approach in the Management of Morbidly Adherent Placenta With Maternal Morbidity and Mortality. Obstet Gynecol. 2018;132(5):1167-76. [Crossref]  [PubMed]
  29. Chandraharan E, Rao S, Belli AM, Arulkumaran S. The Triple-P procedure as a conservative surgical alterna- tive to peripartum hysterectomy for placenta percreta. Int J Gynaecol Obstet. 2012;117(2):191-4. [Crossref]  [PubMed]
  30. Silver RM, Barbour KD. Placenta accreta spectrum: ac- creta, increta, and percreta. Obstet Gynecol Clin North Am. 2015;42(2):381-402. [Crossref]  [PubMed]
  31. Society of Gynecologic O, American College of O, Gyne- cologists, the Society for Maternal-Fetal M, Cahill AG, Beigi R, et al. Placenta Accreta Spectrum. Am J Obstet Gynecol. 2018;219(6):B2-B16. [Crossref]  [PubMed]
  32. Committee on Obstetric P. ACOG committee opinion. Placenta accreta. Number 266, January 2002. American College of Obstetricians and Gynecologists. Int J Gy- naecol Obstet. 2002;77(1):77-8. [Crossref]  [PubMed]
  33. Jauniaux E, Alfirevic Z, Bhide AG, Belfort MA, Bur- ton GJ, Collins SL, et al. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guide- line No. 27a. BJOG. 2019;126(1):e1-e48. [Crossref]  [PubMed]
  34. Gyamfi-Bannerman C, Thom EA. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016;375(5):486-7. [Crossref]  [PubMed]
  35. Robinson BK, Grobman WA. Effectiveness of timing strat- egies for delivery of individuals with placenta previa and accreta. Obstet Gynecol. 2010;116(4):835-42. [Crossref]  [PubMed]
  36. Flood KM, Said S, Geary M, Robson M, Fitzpatrick C, Malone FD. Changing trends in peripartum hysterectomy over the last 4 decades. Am J Obstet Gynecol. 2009;200(6):632 e1-6. [Crossref]  [PubMed]
  37. Shamshirsaz AA, Fox KA, Erfani H, Belfort MA. The Role of Centers of Excellence With Multidisciplinary Teams in the Management of Abnormal Invasive Placenta. Clin Ob- stet Gynecol. 2018;61(4):841-50. [Crossref]  [PubMed]
  38. Shamshirsaz AA, Fox KA, Erfani H, Clark SL, Sham- shirsaz AA, Nassr AA, et al. Outcomes of Planned Com- pared With Urgent Deliveries Using a Multidisciplinary Team Approach for Morbidly Adherent Placenta. Obstet Gynecol. 2018;131(2):234-41. [Crossref]  [PubMed]
  39. Bowman ZS, Manuck TA, Eller AG, Simons M, Silver RM. Risk factors for unscheduled delivery in patients with pla- centa accreta. Am J Obstet Gynecol. 2014;210(3):241 e1-6. [Crossref]  [PubMed]
  40. Rac MWF, Wells CE, Twickler DM, Moschos E, McIntire DD, Dashe JS. Placenta accreta and vaginal bleeding according to gestational age at delivery. Obstet Gynecol. 2015;125(4):808-13. [Crossref]  [PubMed]
  41. Vassallo R, Goldman M, Germain M, Lozano M, Col- laborative B. Preoperative Autologous Blood Donation: Waning Indications in an Era of Improved Blood Safe- ty. Transfus Med Rev. 2015;29(4):268-75. [Crossref]  [PubMed]
  42. Waters JH, Biscotti C, Potter PS, Phillipson E. Amniot- ic fluid removal during cell salvage in the cesarean section patient. Anesthesiology. 2000;92(6):1531-6. [Crossref]  [PubMed]
  43. Shamshirsaz AA, Fox KA, Erfani H, Clark SL, Salmanian B, Baker BW, et al. Multidisciplinary team learning in the man- agement of the morbidly adherent placenta: outcome improve- ments over time. Am J Obstet Gynecol. 2017;216(6):612 e1- e5. [Crossref]  [PubMed]
  44. Panigrahi AK, Yeaton-Massey A, Bakhtary S, Andrews J, Lyell DJ, Butwick AJ, et al. A Standardized Approach for Transfusion Medicine Support in Patients With Morbidly Ad- herent Placenta. Anesth Analg. 2017;125(2):603-8. [Crossref]  [PubMed]
  45. Committee on Practice B-O. Practice Bulletin No. 183: Post- partum Hemorrhage. Obstet Gynecol. 2017;130(4):e168-e86. [Crossref]  [PubMed]
  46. Palacios-Jaraquemada JM. Caesarean section in cases of placenta praevia and accreta. Best Pract Res Clin Obstet Gynaecol. 2013;27(2):221-32. [Crossref]  [PubMed]
  47. Tam Tam KB, Dozier J, Martin JN, Jr. Approaches to reduce urinary tract injury during management of placenta accreta, increta, and percreta: a systematic review. J Matern Fetal Neonatal Med. 2012;25(4):329-34. [Crossref]  [PubMed]
  48. Merritt AJ, Crosbie EJ, Charova J, Achiampong J, Zom- mere I, Winter-Roach B, et al. Prophylactic pre-operative bilateral ureteric catheters for major gynaecological sur- gery. Arch Gynecol Obstet. 2013;288(5):1061-6. [Crossref]  [PubMed]